MX343540B - Compuesto de tiazol y metodo de preparacion y uso del mismo. - Google Patents

Compuesto de tiazol y metodo de preparacion y uso del mismo.

Info

Publication number
MX343540B
MX343540B MX2013013048A MX2013013048A MX343540B MX 343540 B MX343540 B MX 343540B MX 2013013048 A MX2013013048 A MX 2013013048A MX 2013013048 A MX2013013048 A MX 2013013048A MX 343540 B MX343540 B MX 343540B
Authority
MX
Mexico
Prior art keywords
preparation
thiazole compound
invention disclosed
present
antitumor
Prior art date
Application number
MX2013013048A
Other languages
English (en)
Other versions
MX2013013048A (es
Inventor
Ding Jian
Nan Fajun
Chen Fei
Zhang Yangming
Li Jia
Zhou Yubo
Su Mingbo
Meng Linghua
Xie Xin
Wang Shixian
Original Assignee
Shanghai Puyi Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Puyi Chemical Co Ltd filed Critical Shanghai Puyi Chemical Co Ltd
Publication of MX2013013048A publication Critical patent/MX2013013048A/es
Publication of MX343540B publication Critical patent/MX343540B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención describe una clase de compuestos de tiazol de la fórmula general (I) (ver Fórmula) el método de preparación y uso de los mismos. Más particularmente, la presente invención describe un derivado de largazol de producto natural, el método de preparación del mismo y el uso en el campo de tratamiento de antitumor y esclerosis múltiple como un inhibidor de histona desacetilasa.
MX2013013048A 2011-05-10 2012-05-07 Compuesto de tiazol y metodo de preparacion y uso del mismo. MX343540B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110120207.9A CN102775368B (zh) 2011-05-10 2011-05-10 一类噻唑类化合物及其制备方法和用途
PCT/CN2012/075142 WO2012152208A1 (zh) 2011-05-10 2012-05-07 一类噻唑类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2013013048A MX2013013048A (es) 2014-09-25
MX343540B true MX343540B (es) 2016-11-08

Family

ID=47120501

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013048A MX343540B (es) 2011-05-10 2012-05-07 Compuesto de tiazol y metodo de preparacion y uso del mismo.

Country Status (10)

Country Link
US (1) US9216962B2 (es)
EP (1) EP2708534B1 (es)
JP (1) JP6236382B2 (es)
KR (1) KR101577520B1 (es)
CN (1) CN102775368B (es)
AU (1) AU2012253019B2 (es)
BR (1) BR112013028894B1 (es)
CA (1) CA2835705C (es)
MX (1) MX343540B (es)
WO (1) WO2012152208A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133166B2 (en) * 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CN104974108B (zh) * 2014-04-04 2017-11-17 中国科学院上海药物研究所 一类2,2’‑串联双噻唑类化合物及其制备方法和用途
US10065948B2 (en) * 2014-06-02 2018-09-04 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
CN105315226A (zh) * 2014-07-11 2016-02-10 中国科学院生态环境研究中心 一种以羧酸为底物一锅法合成2,4-二取代噻唑的新方法
JP6507267B2 (ja) 2015-05-22 2019-04-24 チョン クン ダン ファーマシューティカル コーポレーション 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物
CN107793375A (zh) * 2016-08-31 2018-03-13 中国科学院上海药物研究所 一类芳基2,2’‑串联双噻唑类化合物及其制备方法和用途
KR102690225B1 (ko) 2019-04-03 2024-07-30 프라임진(베이징) 코., 엘티디. 퀴놀린 함유 화합물, 의약 조성물 및 그의 용도
AU2021230289A1 (en) * 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
EP4308097A4 (en) * 2021-03-15 2025-08-20 Univ Michigan Regents NON-HYDROXAMATE HDAC6 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200861B1 (pl) * 1999-09-08 2009-02-27 Sloan Kettering Inst Cancer Pochodna kwasu suberynowego, jej zastosowanie i kompozycja farmaceutyczna
ATE310719T1 (de) * 2000-09-29 2005-12-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
CA2463552C (en) * 2001-10-16 2011-05-17 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
WO2003070691A1 (en) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
CN1768031A (zh) * 2003-04-07 2006-05-03 Axys药物公司 作为治疗剂的异羟肟酸酯
US7842835B2 (en) * 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1644323B1 (en) * 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
CA2535350A1 (en) * 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
AR046605A1 (es) * 2003-10-27 2005-12-14 S Bio Pte Ltd Hidroxamatos unidos a biarilo; preparacion y aplicaciones farmaceuticas
CN101001851B (zh) * 2004-08-09 2011-04-20 安斯泰来制药有限公司 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物
CN101035542A (zh) * 2004-08-25 2007-09-12 默克公司 组蛋白脱乙酰基酶抑制剂
AR050552A1 (es) * 2004-09-02 2006-11-01 Osi Pharm Inc Mercaptoamidas como inhibidores de histona desacetilasa
ITFI20050041A1 (it) * 2005-03-15 2006-09-16 Menarini Internat Operations Luxembourg Sa Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
CN1834095B (zh) * 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
CN101163690A (zh) * 2005-04-20 2008-04-16 默克公司 苯并噻吩异羟肟酸衍生物
WO2008019025A2 (en) * 2006-08-03 2008-02-14 Georgetown University Isoform-selective hdac inhibitors
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
EP2217588A4 (en) * 2007-11-02 2013-12-04 Methylgene Inc INHIBITORS OF HISTONE DEACETYLASE
CA2735593C (en) * 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors

Also Published As

Publication number Publication date
EP2708534B1 (en) 2017-07-12
US9216962B2 (en) 2015-12-22
KR20140028046A (ko) 2014-03-07
US20140148600A1 (en) 2014-05-29
BR112013028894B1 (pt) 2021-06-29
WO2012152208A1 (zh) 2012-11-15
BR112013028894A2 (pt) 2016-09-06
EP2708534A1 (en) 2014-03-19
MX2013013048A (es) 2014-09-25
CN102775368B (zh) 2016-08-17
CN102775368A (zh) 2012-11-14
KR101577520B1 (ko) 2015-12-14
AU2012253019B2 (en) 2016-03-03
CA2835705A1 (en) 2012-11-15
NZ617505A (en) 2015-11-27
CA2835705C (en) 2016-01-19
AU2012253019A1 (en) 2013-11-28
JP6236382B2 (ja) 2017-11-22
EP2708534A4 (en) 2015-02-18
JP2014517831A (ja) 2014-07-24

Similar Documents

Publication Publication Date Title
MX343540B (es) Compuesto de tiazol y metodo de preparacion y uso del mismo.
AU2012214029A8 (en) Rorgammat inhibitors
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PH12017502141A1 (en) Compounds and their methods of use
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
PH12014500987A1 (en) Neprilysin inhibitors
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
IN2014MN01183A (es)
IN2014DN10670A (es)
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
IN2014CN04676A (es)
PH12014500759A1 (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
TN2014000095A1 (en) Pharmaceutical compositions
MX2013006802A (es) Inhibidores de neprilisina.
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
CY1121825T1 (el) Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
PH12013501561A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
AU2012225365A8 (en) Peptide deformylase inhibitors
MX2013006185A (es) Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos.
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch

Legal Events

Date Code Title Description
FG Grant or registration